Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Incy save search
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.45%
H: 0.52%
C: -0.94%
incb5470 positive study
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Published: 2023-07-24 (Crawled : 11:00) - prnewswire.com
SNDX | $20.79 -0.86% -0.87% 370K
|
Health Technology
|
| O: 8.18%
H: 2.39%
C: -5.35%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.17%
H: 0.37%
C: -1.24%
agave-201 disease positive topline trial results
Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-06-19 (Crawled : 20:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.41%
H: 2.02%
C: 1.37%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.3%
H: 0.17%
C: -2.63%
positive show growth study market
Significant Positive Shift in the Cell and Gene Therapies in Rare Disorders Market with 35.8% CAGR During the Study Period (2019-2032) Expected by Analysts at DelveInsight
Published: 2023-05-09 (Crawled : 15:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.35%
H: 0.23%
C: -0.43%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.61%
H: 0.49%
C: -0.95%
rare expected positive cell study market
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
Published: 2023-05-02 (Crawled : 12:20) - mindmed.co
MNMD | $8.45 -4.74% -4.97% 830K
|
n/a
|
| O: -1.04%
H: 0.79%
C: -1.06%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.2%
H: 2.1%
C: -0.59%
ALC | $79.57 -1.47% 0.0% 850K
|
Health Technology
|
| O: -0.69%
H: 0.77%
C: 0.11%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.28%
H: 0.32%
C: 0.11%
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.5%
H: 0.74%
C: -2.58%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -9.64%
H: 5.99%
C: 2.76%
FBRX 4 | $0.711 -3.74% -4.03% 14K
|
Health Technology
|
| O: -1.85%
H: 4.72%
C: 0.94%
momentum positive
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
Published: 2023-02-24 (Crawled : 13:00) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.3%
H: 0.14%
C: -0.53%
treatment chmp positive
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
Published: 2022-04-22 (Crawled : 16:00) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.4%
H: 1.01%
C: 0.04%
tabrecta treatment chmp positive cancer
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 02:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
phase 2 heart positive trial
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-06-25 (Crawled : 13:00) - biospace.com/
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 0.06%
H: 2.35%
C: 0.75%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.71%
H: 1.74%
C: 1.53%
treatment positive chmp t-cell
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-06-25 (Crawled : 12:15) - biospace.com/
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 0.06%
H: 2.35%
C: 0.75%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.71%
H: 1.74%
C: 1.53%
treatment positive chmp t-cell
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
Published: 2021-05-17 (Crawled : 12:15) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.18%
H: 1.7%
C: -0.24%
positive results positive results phase 3
Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
Published: 2021-01-29 (Crawled : 00:00) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.31%
H: 1.29%
C: -1.36%
positive treatment growth chmp
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.